Tracking SARS-CoV-2 variants

All viruses, including SARS-CoV-2, the virus that causes COVID-19, change over time. Most changes have little to no impact on the virus’s properties. However, some changes may affect the virus’s properties, such as how easily it spreads, the associated disease severity, or the performance of vaccines, therapeutic medicines, diagnostic tools, or other public health and social measures. 

In June 2020, the WHO Virus Evolution Working Group was established with a specific focus on SARS-CoV-2 variants, their phenotype and their impact on countermeasures. This later became the Technical Advisory Group on SARS-CoV-2 Virus Evolution. In late 2020, the emergence of variants that posed an increased risk to global public health prompted WHO to characterize some as variants of interest (VOIs) and variants of concern (VOCs) in order to prioritize global monitoring and research, and to inform and adjust the COVID-19 response. From May 2021 onwards, WHO began assigning simple, easy-to-say labels for key variants.

Considerable progress has been made in establishing and strengthening a global system to detect signals of potential VOIs or VOCs and rapidly assess the risk posed by SARS-CoV-2 variants to public health. It remains critical that these systems are maintained, and data are shared, according to good principles and in a timely fashion, as SARS-CoV-2 continues to circulate at high levels around the world. While monitoring the circulation of SARS-CoV-2 globally, it also remains essential to monitor their spread in animal populations and chronically infected individuals, which are crucial aspects of the global strategy to reduce the occurrence of mutations that have negative public health implications. In March 2023, WHO updated its tracking system and working definitions for variants of concern, variants of interest and variants under monitoring. They can be found here. The previous working definitions can be found here.

 

Currently circulating variants of concern (VOCs) as of 15 March 2023

Currently circulating variants of interest (VOIs) as of 05 June 2023

 

Pango lineageNextstrain cladeGenetic featuresEarliest documented samplesDate of designation and risk assessments
XBB.1.523A
Recombinant of BA.2.10.1 and BA.2.75 sublineages, i.e. BJ1 and BM.1.1.1, with a breakpoint in S1. 

XBB.1 + S:F486P (similar Spike genetic profile as XBB.1.9.1)

05-01-2022
11-01-2023




XBB.1.1623B

Recombinant of BA.2.10.1 and BA.2.75 sublineages, i.e. BJ1 and BM.1.1.1

XBB.1 + S:E180V, S:K478R and S:F486P
09-01-2023

17-04-2023

XBB.1.16 Initial Risk Assessment, 17 April 2023

XBB.1.16 Updated Risk Assessment, 05 June 2023

 

Currently circulating variants under monitoring (VUMs) (as of 17 May 2023)

 

Pango lineageNextstrain cladeGenetic featuresEarliest documented samplesDate of designation and risk assessments
BA.2.7522DBA.2 + S:K147E, S:W152R, S:F157L, S:I210V, S:G257S, S:D339H, S:G446S, S:N460K, S:Q493R reversion31-12-202106-07-2022
CH.1.122DBA.2.75 + S:L452R, S:F486S27-07-202208-02-2023
BQ.122EBA.5 + S:R346T, S:K444T, S:N460K07-02-202221-09-2022
XBB*22FBA.2+ S:V83A, S:Y144-, S:H146Q, S:Q183E, S:V213E, S:G252V, S:G339H, S:R346T, S:L368I, S:V445P, S:G446S, S:N460K, S:F486S, S:F490S13-08-202212-10-2022
XBB.1.9.1Not assigned

Recombinant of BA.2.10.1 and BA.2.75 sublineages, i.e. BJ1 and BM.1.1.1

 

XBB.1 + S:F486P (similar Spike genetic profile as XBB.1.5)

05-12-202230-03-2023
XBB.1.9.2Not assigned

Recombinant of BA.2.10.1 and BA.2.75 sublineages, i.e. BJ1 and BM.1.1.1

XBB.1 + S:F486P, S:Q613H

05-12-202226-04-2023
XBB.2.3Not assigned

Recombinant of BA.2.10.1 and BA.2.75 sublineages, i.e. BJ1 and BM.1.1.1

 

XBB + S:D253G, S:F486P, S:P521S

09-12-202217-05-2023

* Excludes XBB sublineages listed here as VOIs and VUMs

 

Publications

All →
WHO guiding principles for pathogen genome data sharing

WHO encourages the sharing of pathogen genome data to protect global public health. Sharing of pathogen genome data is critical for preventing, detecting,...

Guidance for surveillance of SARS-CoV-2 variants: Interim guidance, 9 August 2021

This document aims to describe a minimum set of surveillance activities recommended at the national level to detect and monitor the relative prevalence...

SARS-CoV-2 genomic sequencing for public health goals: Interim guidance, 8 January 2021

The growing understanding of how sequence information can contribute to improved public health is driving global investments in sequencing facilities and...

Genomic sequencing of SARS-CoV-2: a guide to implementation for maximum impact on public health

Sequencing enabled the world to rapidly identify SARS-CoV-2 and develop diagnostic tests and other tools for outbreak management. Continued genome sequencing...